About us

Overview

30 Technology is a privately owned biopharmaceutical company developing nitric oxide-generating technologies for healthcare applications, that represent the most significant advance in combating anti-microbial resistant infections in over 50 years.


Our proprietary NO-generating platform safely delivers sustained, high-dose nitric oxide in multiple forms (e.g., an inhaled liquid, topical gel, or dry powder), at multiple doses, and for durations ranging from hours to days. This exceptional customisability makes it ideal for use in a broad range of clinical applications, with 30 Technology initially targeting respiratory disease, oral health, dermatology, rare diseases and animal health.

We sold our first product for healing Diabetic Foot Ulcers to Convatec in 2023 for over $225m. Now launched in multiple markets under the name ConvaNiox, it was awarded EWMA’s Innovation of the Year in 2026. Read more here.

Our lead respiratory candidate RESP303 is a first-in-class inhaled antimicrobial therapy that generates nitric oxide directly at the airway surface to treat chronic multidrug-resistant respiratory infection in Cystic Fibrosis patients, and Pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis (NCFB).

RESP303 is not just another single-action inhaled antibiotic. By producing nitric oxide it exerts antimicrobial activity through multiple simultaneous mechanisms, including oxidative stress, membrane disruption, protein inactivation, DNA damage and crucially, biofilm disruption. Microbes would require multiple simultaneous mutations to develop resistance to these multiple mechanisms, making resistance development significantly less likely than with conventional antibiotics.

This positions RESP303 as a potential new antimicrobial class for chronic respiratory infections.

Further details can be found here.

Partnerships

We have built a strong network of strategic alliances with leading experts in healthcare to advance our research programs and develop new applications.

30 Technology is always looking to collaborate with academic researchers and thought leaders to better understand the role of nitric oxide in human health and diseases.

If you are interested in collaborating, please contact us at innovation@30.technology

Leadership team

SYD HANNA Group Executive Director
read more
Syd joined 30 Technology in 2012 and led the business’s growth, strategy, financing, and research program. Syd has extensive experience founding and building businesses for long-term value with private and institutional backing across the drug discovery, medical device and service sectors. Syd has board level experience of several early-stage biopharmaceutical companies and is a Chartered Global Management Accountant.
DR SYED JAFRI Group Executive Director and Chief Medical Officer
read more
Syed joined 30 Technology’s Executive Leadership team in 2021. Prior to this, he was Head of Clinical Development at Linde plc where he led the clinical development and launch of multiple respiratory and cardiovascular products including inhaled nitric oxide. With over 20 years of experience in drug/device development and product commercialisation, Syed brings a wealth of experience across the clinical, commercial and strategic arenas as well as considerable expertise in clinical asset portfolio management and growth.
DR KEITH LIPMAN Group Executive Director
read more
Keith leads the Research and Development team. Keith earned his BA (Natural Sciences) and PhD (Astrophysics) from Cambridge University, researching the creation of Nitrogen and Oxygen in the primeval universe. His career has spanned creation and scaling of scientific and research-led businesses and joined 30 Technology in 2018.
PROF. CHRIS WOOD Chairman and Founder
read more
Chris has more than 20 years of experience in the biotechnology sector, having founded, managed and successfully exited Bioenvision Inc. among others. Prior to this Chris was a consultant surgeon at the Royal Postgraduate Medical School.


Strategic Advisors

DR. ANDY WEYMANN Senior Medical Advisor
read more
Andy joined Thirty’s Executive Leadership in 2020. Immediately prior to joining Thirty, Andy was Chief Medical Officer for Smith & Nephew, where he provided global leadership and oversight of Clinical, Scientific and Medical Affairs with accountability for patient and product safely. He also served on the Board of Smith & Nephew’s subsidiaries/acquired companies. Today Andy is CEO / Director of the Board of Gelmetix a spine company, and also chairs the Board of Jellagen and SolasCure. Andy played a key role in the divestment of 30 Technology’s woundcare business to Convatec through his medical leadership. Prior to his corporate career, Andy was a physician in Switzerland practising in trauma and orthopaedic surgery, having obtained his Masters in Human Medicine at the University of Zurich, Switzerland. Following his time as a Medical Doctor, Andy completed his MBA degree at the Graduate School of Business, University of Rochester and did his Board Program at Harvard Business School, Boston.

Scientific Advisory Board

DR CHARLES HAWORTH Scientific Board Member
read more
  • Head of Pulmonary Medicine & Research Director of the Cambridge Centre for Lung Infection at Papworth Hospital
  • Co-Author of the US Cystic Fibrosis Foundation & European Cystic Fibrosis Society and UK British Thoracic Society NTM guidelines
PROF. ANTHONY DE SOYZA Scientific Board Member
read more
  • Professor of Pulmonary Medicine at Newcastle University
  • Academic Clinician / Physician-Researcher and an Honorary Consultant Physician at Newcastle upon Tyne Hospitals NHS Foundation Trust
  • UK and International lead investigator in multiple clinical trials
  • National Specialty lead for the NIHR National Respiratory group
PROF. STUART ELBORN CBE Scientific Board Member
read more
  • Pro-Vice Chancellor at Queens University Belfast and global expert on CF and NCFB
  • Previously Clinical Professor of Respiratory Medicine and Director of Adult Cystic Fibrosis and Chronic Lung Infection at the NHLI, Imperial College London and Royal Brompton Hospital London
  • Principal Investigator on multiple inhaled antibiotic studies
  • Head of Queens University Belfast CF/NCFB Research Lab
PROF. MICHAEL LOEBINGER Scientific Board Member
read more
  • Professor of Respiratory Medicine at Imperial London and Consultant Respiratory Physician at Royal Brompton Hospital London
  • Co-author of UK and EU bronchiectasis guidelines
  • ERS Respiratory Infection Chair
  • Global expert on NCFB and NTM/PA
  • Clinical Director of Laboratory Medicine at Royal Brompton & Harefield Hospitals NHS Foundation Trust